Compare NPKI & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | COAG |
|---|---|---|
| Founded | 1932 | N/A |
| Country | United States | United States |
| Employees | 510 | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | N/A | 2026 |
| Metric | NPKI | COAG |
|---|---|---|
| Price | $14.27 | $31.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.17 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 252.9K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.39 | N/A |
| Revenue Next Year | $11.70 | N/A |
| P/E Ratio | $38.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.17 | $27.47 |
| 52 Week High | $16.50 | $38.87 |
| Indicator | NPKI | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 48.05 |
| Support Level | $13.70 | $27.47 |
| Resistance Level | $15.28 | $38.87 |
| Average True Range (ATR) | 0.77 | 3.96 |
| MACD | -0.06 | 0.21 |
| Stochastic Oscillator | 13.16 | 30.96 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom. It generates maximum revenue from United States.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.